← All trials
NCT04022967
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2019
- Primary completion
- Oct 15, 2022
- Completion date
- Oct 15, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of FranceLead sponsor
- MylanCollaborator
- University of ParisStudy chair
- CHU TreichvilleOverall official - principal investigator
- University of ParisOverall official - principal investigator
- University of BordeauxStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.